Vincent Vultaggio

CIK: 0002018766

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)7 (77.8%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (22.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ZNTL

Zentalis Pharmaceuticals, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 10, 2026
Sale(S)
Direct
6.9K shares at avg. $2.42$17K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 9, 2026
Sale(S)
Direct
3.4K shares at avg. $2.39$8K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 6, 2026
Sale(S)
Direct
30K shares at avg. $2.43$73K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 3, 2026
Sale(S)
Direct
556 shares at avg. $2.52$1K
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 2, 2026
Sale(S)
Direct
2.5K shares at avg. $2.55$6K
ZNTL
Zentalis Pharmaceuticals, Inc.
Jan 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 3, 2025
Award(A)
Direct
158.6K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Feb 3, 2025
Sale(S)
Direct
2.6K shares at avg. $1.71$4K
ZNTL
Zentalis Pharmaceuticals, Inc.
Oct 4, 2024
Sale(S)
Direct
1.6K shares at avg. $3.18$5K

		Type	Shares	Price		Ownership
Feb 10, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	6,894	$2.42	$16,699	Direct
Feb 9, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	3,379	$2.39	$8,086	Direct
Feb 6, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	29,951	$2.43	$72,772	Direct
Feb 3, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	556	$2.52	$1,398	Direct
Feb 2, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	2,540	$2.55	$6,477	Direct
Jan 8, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Feb 3, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	158,586	-	-	Direct
Feb 3, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	2,615	$1.71	$4,476	Direct
Oct 4, 2024	ZNTL Zentalis Pharmaceuticals, Inc.	Sale(S)	1,603	$3.18	$5,098	Direct

1-9 of 9 transactions

About Vultaggio Vincent

Vultaggio Vincent (SEC CIK 0002018766) files insider reports with the SEC as PAO and PFO of Zentalis Pharmaceuticals, Inc. (ZNTL).

Signal8 holds 5 ownership filings by Vultaggio Vincent, all Form 4s, filed between Oct 4, 2024 and Feb 10, 2026. Those filings report 9 transactions, from Oct 4, 2024 to Feb 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Vultaggio Vincent's filings is in SAN DIEGO, CA.

Recent filings by Vultaggio Vincent

Feb 10, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Feb 9, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Feb 6, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Feb 3, 2026: Open-market sale of ZNTL shares (Form 4, code S).
Feb 2, 2026: Open-market sale of ZNTL shares (Form 4, code S).

Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)

Bruns Ingmar, Chief Medical Officer
WALTERS GROUP, 10% Owner
Johnson David Michael, Director
Skvarka Jan, Director
Walker Luke Nathaniel, Director
Kariuki Enoch, Director

How to read Form 4 transaction codes